PharmaTimes4d
FDA approves Deciphera’s Romvimza for rare tumour type
The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat adults with ...
News Medical on MSN3d
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
Monthly Prescribing Reference5d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
BioWorld5d
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
BioSpace6d
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
GlobalData on MSN6d
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...
Pharmabiz3d
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval: Osaka Friday, February 21, 2025, 15:00 Hrs [IST] Ono Pharmaceutical, one of the la ...
MedCity News6d
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
The twice-weekly capsule will be marketed under the brand name Romvimza. TGCT stems from a genetic abnormality that results in overexpression of a protein called colony-stimulating factor receptor.